News | May 22, 2024
AstraZeneca plans $1.5 billion ADCs manufacturing facility in Singapore
Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs
Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs
Launch of 20 new medicines expected by 2030
Very strong revenue and EPS growth in the first quarter coupled with exciting pipeline delivery
Evinova will operate as a separate health-tech business within AstraZeneca
New reforestation projects in Brazil, India, Vietnam, Ghana and Rwanda in addition to existing projects including in Australia and Indonesia
Move brings together AstraZeneca and Alexion colleagues in a purpose-built facility in Kendall Square, Cambridge, MA, a world-leading life sciences hub
Further demonstrates Honeywell's commitment to greenhouse gas reduction and support of customers' sustainability goals through innovative new products
New inhalers would have near-zero Global Warming Potential propellant
State-of-the-art R&D facility designed to foster collaboration across world-class science ecosystem
The investment programme is expected to significantly reduce commercialisation lead times, costs and introduce more sustainable manufacturing processes
Subscribe To Our Newsletter & Stay Updated
